The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s muscle relaxant drugs market report forecasts the muscle relaxant drugs market size to grow to $5.79 Billion by 2027, with a CAGR (compound annual growth rate) of more than 6%.

Learn More On The Muscle Relaxant Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

Muscle Relaxant Drugs Market Size Forecast
The global muscle relaxant drugs market is expected to grow from $4.13 billion in 2022 to $4.45 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The muscle relaxant drugs market is expected to reach $5.79 billion in 2027 at a CAGR of 6.8%.

North America held the largest muscle relaxant drugs market share.

Key Muscle Relaxant Drugs Market Driver ­– Rise In The Geriatric Population
According to the United Nations Department of Economic and Social Affairs’ September 2020 report, the population aged 65 and up is expected to increase from 9.3% in 2020 to around 16.0% in 2050. Furthermore, according to a World Health Organization factsheet published in October 2021, there will be 1.4 billion people over the age of 60 in the world by 2030, up from 1 billion in 2020. As a result, the growing geriatric population is propelling the muscle relaxant drugs market forward.

Request for A Sample Of The Global Muscle Relaxant Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8751&type=smp

Key Muscle Relaxant Drugs Market Trend – Product Innovations
To maintain their market position, major players are developing innovative drugs for specific medical applications such as generic versions of muscle relaxant drugs, muscle relaxants for animals, drugs with flexible, customised dosing, and others. Amneal Pharmaceuticals Inc., a US-based integrated specialty pharmaceutical company, for example, launched LYVISPAH® in June 2022, a baclofen oral granule (5, 10, and 20 mg) specialty product approved by the US Food and Drug Administration for the treatment of spasticity associated with multiple sclerosis and other spinal cord disorders. LYVISPAHi provides flexible, customised dosing with single-dose packets of 5mg, 10mg, and 20mg granules used to treat muscle stiffness, spasms, and pain associated with multiple sclerosis. For patients with spasticity who also have difficulty swallowing pills, the rapidly dissolving flavoured granules provide an alternative. The medication can be given to the patient in three ways: directly into the patient’s mouth with or without water, mixed with liquids or foods, or via an enteral feeding tube.

Muscle Relaxant Drugs Market Segment
1) By Drug Type: Facial Muscle Relaxant Drugs, Skeletal Muscle Relaxant Drugs, Neuromuscular Blocking Agents
2) By Route of Administration: Oral, Injectable, Spray, Ointment
3) By Formulation: Cyclobenzaprine, Carisoprodol, Chlorzoxazone, Metaxalone, Methocarbamol, Baclofen, Tizanidine, Orphenadrine, Dantrolene
4) By End-User: Hospitals, Homecare, Speciality Clinics, Other End-Users

Muscle Relaxant Drugs Market Major Players and Strategies
Major players in the muscle relaxant drugs market are Pfizer Inc., Ipsen Pharma, Teijin Limited, Par Pharmaceutical, Orient Pharma, Sandoz International GmbH, Accord Healthcare, Amneal Pharmaceuticals LLC, Fresenius Kabi India Pvt. Ltd., Aurobindo Pharma, Mylan N.V., Hikma Pharmaceuticals PLC, Lupin, Akorn Incorporated, and Merck & Co. Inc.

AbbVie, a global biopharmaceutical company based in the United States, paid an undisclosed sum for Allergan plc in 2020. The transaction significantly broadens and diversifies AbbVie’s revenue stream and strengthens the company’s already-established leadership positions in immunology with Humira®, hematologic oncology with Imbruvica®, and hematologic oncology with Rinvoq®. Allergan plc is a US-based pharmaceutical company that manufactures and sells muscle relaxants.

The Muscle Relaxant Drugs Global Market Report 2023 covers regional data on muscle relaxant drugs market size, muscle relaxant drugs market trends and drivers, opportunities, strategies, and muscle relaxant drugs market competitor analysis. The countries covered in the muscle relaxant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Muscle relaxants are drugs used to treat muscle spasms caused by neurological conditions. These are used to treat muscle aches and pains.

View More Reports Related To The Muscle Relaxant Drugs Market –
Drug Delivery Devices Global Market Report 2023
Drugs For Immunotherapy Global Market Report 2023
Drug Discovery Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: